Kewaunee Upgraded to Outperform on Nu Aire Synergies, Backlog

Kewaunee Scientific (KEQU) received an "Outperform" upgrade, driven by the transformative Nu Aire acquisition which boosted fiscal 2025 domestic sales by 30.7% to $179.4 million and expanded gross margins by 310 basis points to 28.6%. A record $214.6 million backlog, up 37.9% year-over-year, provides strong revenue visibility and macro-economic insulation through healthcare exposure, positioning KEQU for continued growth despite minor international headwinds and tariff risks.

Analysis

Kewaunee Scientific Corporation (KEQU) has demonstrated a significant operational and financial transformation following its November 2024 acquisition of Nu Aire, Inc., underpinning a recent 'Outperform' rating. The acquisition has been immediately accretive, driving a 30.7% year-over-year increase in domestic sales to $179.4 million for fiscal 2025 and expanding the company's portfolio into higher-margin products. This strategic shift is reflected in a meaningful profitability improvement, with gross margins expanding 310 basis points to 28.6% and adjusted EBITDA climbing 28.4% to $26.5 million, even after absorbing $6 million in one-time integration costs. Future revenue is well-supported by a record backlog of $214.6 million, a 37.9% increase from the prior year, with management projecting 93% of this will convert to revenue in fiscal 2026. This backlog, heavily weighted toward resilient healthcare and life sciences end-markets, provides exceptional near-term visibility and a partial buffer against macroeconomic cyclicality. While risks persist, namely tariff-related cost pressures and a weak international segment where sales fell 8.2%, the robust domestic momentum and strong backlog appear to more than compensate for these headwinds.

Key Decisions for Investors

• Investors should consider the positive operational momentum and successful Nu Aire integration as a primary catalyst for potential upside, with the 'Outperform' rating signaling a favorable risk-reward profile at current levels.
• Monitor the company's ability to convert its record $214.6 million backlog into revenue during fiscal 2026, as this is the key indicator for meeting near-term growth expectations.
• Keep a close watch on gross margin trends for continued evidence of synergy realization, while also tracking potential headwinds from tariff-related input costs and any further deterioration in the international business segment.